Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jazz Pharmaceuticals Total Payout Ratio Related Terms
Jazz Pharmaceuticals Total Payout Ratio Historical Data
* Premium members only.
The historical data trend for Jazz Pharmaceuticals's Total Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:J7Z vs ASND, BBIO, EXEL: Total Payout Ratio Comparison
For the Biotechnology subindustry, Jazz Pharmaceuticals's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jazz Pharmaceuticals Total Payout Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jazz Pharmaceuticals's Total Payout Ratio distribution charts can be found below:
* The bar in red indicates where Jazz Pharmaceuticals's Total Payout Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jazz Pharmaceuticals (FRA:J7Z) has a Total Payout Ratio of 0.00 as of Sep. 10, 2026. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Jazz Pharmaceuticals and its competitors.
Is Jazz Pharmaceuticals' Total Payout Ratio too high?
Jazz Pharmaceuticals' current Total Payout Ratio is 0.00. Overall, Jazz Pharmaceuticals has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jazz Pharmaceuticals' Total Payout Ratio compare to ASND and BBIO?
Jazz Pharmaceuticals' Total Payout Ratio of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Ratio for a Biotechnology company?
A good Total Payout Ratio depends on the Biotechnology industry context. However, Total Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Ratio mean?
A high Total Payout Ratio can signal that a stock is expensive relative to its fundamentals. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Jazz Pharmaceuticals and its competitors. Jazz Pharmaceuticals's current Total Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jazz Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jazz Pharmaceuticals (FRA:J7Z) is currently considered Significantly Overvalued. The stock's GF Value™ is €129.09, compared to a current price of €206.00 — trading 59.6% above its estimated fair value. The current Total Payout Ratio is 0.00. Jazz Pharmaceuticals' overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Ratio calculated?
Total Payout Ratio is calculated from a company's financial statements. For Jazz Pharmaceuticals (FRA:J7Z), the current Total Payout Ratio is 0.00 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jazz Pharmaceuticals (FRA:J7Z) Overvalued in 2026?
Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued.
The current stock price of €206.00 is trading 59.6% above its estimated GF Value™ of €129.09.
GuruFocus considers Jazz Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for FRA:J7Z:
Total Payout Ratio: 0.00
GF Value™: €129.09 vs. price of €206.00 (59.6% above fair value)
No single metric tells the full story. See the FRA:J7Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
74GF Score
Get the complete analysis for FRA:J7Z
Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:J7Z has been successfully added to your 
